Anti-interleukin-6 receptor antibody, tocilizumab, for the treatment of autoimmune diseases

FEBS Letters

Volumn 585, Issue 23, 2011, Pages 3699-3709

  Tanaka, Toshio ^a   Narazaki, Masashi ^a   Kishimoto, Tadamitsu ^a  

^a OSAKA UNIVERSITY   (Japan)

Author keywords

A humanized anti IL 6 receptor antibody; Autoimmune diseases; IL 6; Inflammation; Tocilizumab

Indexed keywords

CHOLESTEROL; COLCHICINE; CORTICOSTEROID; CYCLOSPORIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; INTERLEUKIN 6; LIVER ENZYME; METHOTREXATE; PLACEBO; PREDNISOLONE; TOCILIZUMAB; TRIACYLGLYCEROL;

ADULT ONSET STILL DISEASE; AMYLOIDOSIS; ANAPHYLAXIS; ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; AORTA ARCH SYNDROME; AUTOIMMUNE DISEASE; AUTOINFLAMMATORY DISEASE; BEHCET DISEASE; CHOLESTEROL BLOOD LEVEL; CHRONIC INFLAMMATION; COLORECTAL CANCER; CROHN DISEASE; DIGESTIVE SYSTEM PERFORATION; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; EDEMA; GIANT CELL ARTERITIS; GRAFT VERSUS HOST REACTION; HEPATITIS; HUMAN; HYPERSENSITIVITY REACTION; HYPERTENSION; INFLAMMATORY DISEASE; JUVENILE RHEUMATOID ARTHRITIS; MALIGNANT NEOPLASTIC DISEASE; MONOTHERAPY; MULTIPLE SCLEROSIS; MYELOOPTIC NEUROPATHY; NEUTROPHIL; NONHUMAN; OFF LABEL DRUG USE; POLYMYOSITIS; PRIORITY JOURNAL; RELAPSING POLYCHONDRITIS; REVIEW; RHEUMATIC POLYMYALGIA; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; SIDE EFFECT; SPONDYLOARTHROPATHY; SYSTEMIC DISEASE; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; THROMBOCYTE; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; TUBERCULOSIS; UPPER RESPIRATORY TRACT INFECTION; UVEITIS;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; AUTOIMMUNE DISEASES; HUMANS; INFLAMMATION; MODELS, IMMUNOLOGICAL; RECEPTORS, INTERLEUKIN-6;

EID: 81755184476     PISSN: 00145793     EISSN: 18733468     Source Type: Journal    
DOI: 10.1016/j.febslet.2011.03.023     Document Type: Review

References (156)

1. T. Hirano, K. Yasukawa, H. Harada, T. Taga, Y. Watanabe, T. Matsuda, S. Kashiwamura, K. Nakajima, K. Koyama, A. Iwamatsu, S. Tsunasawa, F. Sakiyama, H. Matsui, Y. Takahara, T. Taniguchi, and T. Kishimoto Complementary DNA for a novel interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin Nature 324 1986 73 76 (Pubitemid 16008419)
2. K. Yamasaki, T. Taga, Y. Hirata, H. Yawata, Y. Kawanishi, B. Seed, T. Taniguchi, T. Hirano, and T. Kishimoto Cloning and expression of the human interleukin-6 (BSF-2/IFN beta 2) receptor Science 241 1988 825 828
3. M. Hibi, M. Murakami, M. Saito, T. Hirano, T. Taga, and T. Kishimoto Molecular cloning and expression of an IL-6 signal transducer, gp130 Cell 63 1990 1149 1157 (Pubitemid 120035064)
4. M. Narazaki, K. Yasukawa, T. Saito, Y. Ohsugi, H. Fukui, Y. Koishihara, G.D. Yancopoulos, T. Taga, and T. Kishimoto Soluble forms of the interleukin-6 signal-transducing receptor component gp130 in human serum possessing a potential to inhibit signals through membrane-anchored gp130 Blood 82 1993 1120 1126 (Pubitemid 23253984)
5. M. Murakami, M. Hibi, N. Nakagawa, T. Nakagawa, K. Yasukawa, K. Yamanishi, T. Taga, and T. Kishimoto IL-6-induced homodimerization of gp130 and associated activation of a tyrosine kinase Science 260 1993 1808 1810 (Pubitemid 23244207)
6. T. Kishimoto, T. Taga, and S. Akira Cytokine signal transduction Cell 76 1994 253 262 (Pubitemid 24046688)
7. S. Pflanz, L. Hibbert, J. Mattson, R. Rosales, E. Vaisberg, J.F. Bazan, J.H. Phillips, T.K. McClanahan, R. de Waal Malefyt, and R.A. Kastelein WSX-1 and glycoprotein 130 constitute a signal-transducing receptor for IL-27 J. Immunol. 172 2004 2225 2231 (Pubitemid 38182370)
8. T. Kishimoto, S. Akira, and T. Taga Interleukin-6 and its receptor: A paradigm for cytokines Science 258 1992 593 597
9. J.S. Stumhofer, E.D. Tait, W.J. Quinn, N. Hosken, B. Spudy, R. Goenka, C.A. Fielding, A.C. O'Hara, A.C. Chen, M.L. Jones, C.J. Saris, S. Rose-John, D.J. Cua, S.A. Jones, M.M. Elloso, J. Grotzinger, M.P. Cancro, S.D. Levin, and C.A. Hunter A role for IL-27p38 as antagonist of gp130-mediated signaling Nat. Immunol. 11 2010 1119 1126
10. S. Crabe, A. Guay-Giroux, A.J. Tormo, D. Duluc, R. Lissilaa, F. Guilhot, U. Mavoungou-Bigouagou, F. Lefouili, I. Cognet, W. Ferlin, G. Elson, P. Jeannin, and J.-F. Gauchat The IL-27 p28 subunit binds cytokine-like factor 1 to form a cytokine regulating NK and T cell activities requiring IL-6R for signaling J. Immunol. 183 2009 7692 7702
11. T. Kishimoto Interleukin-6: from basic science to medicine - 40 years in immunology Annu. Rev. Immunol. 23 2005 1 21 (Pubitemid 40563163)
12. T. Kishimoto The biology of interleukin-6 Blood 74 1989 1 10 (Pubitemid 19187402)
13. E. Nemeth, S. Rivera, V. Gabayan, C. Keller, S. Taudorf, B.K. Pedersen, and T. Ganz IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin J. Clin. Invest. 113 2004 1271 1276 (Pubitemid 39069926)
14. J.P. Liuzzi, L.A. Lichten, S. Rivera, R.K. Blanchard, T.B. Aydemir, M.D. Knutson, T. Ganz, and R.J. Cousins Interleukin-6 regulates the zinc transporter Zip14 in liver and contributes to the hypozincemia of the acute-phase response Proc. Natl. Acad. Sci. USA 102 2005 6843 6848 (Pubitemid 40675404)
15. A. Kimura, and T. Kishimoto IL-6: regulator of Treg/Th17 balance Eur. J. Immunol. 40 2010 1830 1835
16. M. Okada, M. Kitahara, S. Kishimoto, T. Matsuda, T. Hirano, and T. Kishimoto IL-6/BSF-2 functions as a killer helper factor in the in vitro induction of cytotoxic T cells J. Immunol. 141 1998 1543 1549
17. S. Akira, and K. Takeda Toll-like receptor signalling Nat. Rev. Immunol. 4 2004 499 511 (Pubitemid 38931765)
18. S.M. Hurst, T.S. Wilkinson, R.M. McLoughlin, S. Jones, S. Horiuchi, N. Yamamoto, S. Rose-John, G.M. Fuller, N. Topley, and S.A. Jones IL-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment seen during acute inflammation Immunity 14 2001 705 714 (Pubitemid 32592418)
19. S. Kotake, K. Sato, K.J. Kim, N. Takahashi, N. Udagawa, I. Nakamura, A. Yamaguchi, T. Kishimoto, T. Suda, and S. Kashiwazaki Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation J. Bone Miner. Res. 11 1996 88 95 (Pubitemid 26026748)
20. P. Palmqvist, E. Persson, H.H. Conaway, and U.H. Lerner IL-6, leukemia inhibitory factor, and oncostatin M stimulate bone resorption and regulate the expression of receptor activator of NF-kappa B ligand, osteoprotegerin, and receptor activation of NF-kappa B in mouse calvariae J. Immunol. 169 2002 3353 3362 (Pubitemid 35013185)
21. R.L. Jilka, G. Hangoc, G. Girasole, G. Passeri, D.C. Williams, J.S. Abrams, B. Boyce, H. Broxmeyer, and S.C. Manolagas Increased osteoclast development after estrogen loss: mediation by interleukin-6 Science 257 1992 88 91
22. H. Nakahara, J. Song, M. Sugimoto, K. Hagihara, T. Kishimoto, K. Yoshizaki, and N. Nishimoto Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis Arthritis Rheum. 48 2003 1521 1529 (Pubitemid 36682359)
23. R.M. Grossman, J. Krueger, D. Yourish, A. Granelli-Piperno, D.P. Murphy, L.T. May, T.S. Kupper, P.B. Sehgal, and A.B. Gottlieb Interleukin-6 is expressed in high levels in psoriatic skin and stimulates proliferation of cultured human keratinocytes Proc. Natl. Acad. Sci. USA 86 1989 6367 6371 (Pubitemid 19210653)
24. M.R. Duncan, and B. Berman Stimulation of collagen and glycosaminoglycan production in cultured human adult dermal fibroblasts by recombinant human interleukin 6 J. Invest. Dermatol. 97 1991 686 692
25. T. Hirano, T. Taga, K. Yasukawa, K. Nakajima, N. Nakano, F. Takatsuki, M. Shimizu, A. Murashima, S. Tsunasawa, F. Sakiyama, and T. Kishimoto Human B-cell differentiation factor defined by an anti-peptide antibody and its possible role in autoantibody production Proc. Natl. Acad. Sci. USA 84 1987 228 231 (Pubitemid 17013607)
26. K. Yoshizaki, T. Matsuda, N. Nishimoto, T. Kuritani, L. Taeho, K. Aozasa, T. Nakahata, H. Kawai, H. Tagoh, T. Komori, S. Kishimoto, T. Hirano, and T. Kishimoto Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease Blood 74 1989 1360 1367 (Pubitemid 19227448)
27. T. Hirano, T. Matsuda, M. Turner, N. Miyasaka, G. Buchan, B. Tang, K. Sato, M. Shimizu, R. Maid, M. Feldmann, and T. Kishimoto Excessive production of interleukin 6/B cell stimulatory factor-2 in rheumatoid arthritis Eur. J. Immunol. 18 1988 1797 1801 (Pubitemid 19011590)
28. N. Nishimoto, and T. Kishimoto Interleukin-6: from bench to bedside Nat. Clin. Pract. Rheumatol. 2 2006 619 626
29. N. Nishimoto, K. Terao, H. Nakahara, N. Takagi, and T. Kakehi Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease Blood 112 2008 3959 3964
30. J.S. Smolen, D. Aletaha, M. Koeller, M.H. Weisman, and P. Emery New therapies for treatment of rheumatoid arthritis Lancet 370 2007 1861 1874 (Pubitemid 350180008)
31. S. Ohshima, Y. Saeki, T. Mima, M. Sasai, K. Nishioka, S. Nomura, M. Kopf, Y. Katada, T. Tanaka, M. Suemura, and T. Kishimoto Interleukin 6 plays a key role in the development of antigen-induced arthritis Proc. Natl. Acad. Sci. USA 95 1998 8222 8226 (Pubitemid 28326094)
32. T. Alonzi, E. Fattori, D. Lazzaro, P. Costa, L. Probert, G. Kollias, F. De Benedetti, V. Poli, and G. Ciliberto Interleukin 6 is required for the development of collagen-induced arthritis J. Exp. Med. 187 1998 461 468 (Pubitemid 28093348)
33. M. Sasai, Y. Saeki, S. Ohshima, K. Nishioka, T. Mima, T. Tanaka, Y. Katada, K. Yoshizaki, M. Suemura, and T. Kishimoto Delayed onset and reduced severity of collagen-induced arthritis in interleukin-6-deficient mice Arthritis Rheum. 42 1999 1635 1643 (Pubitemid 30263631)
34. N. Takagi, M. Mihara, Y. Moriya, N. Nishimoto, K. Yoshizaki, T. Kishimoto, Y. Takeda, and Y. Ohsugi Blockade of interleukin-6 receptor ameliorates joint disease in murine collagen-induced arthritis Arthritis Rheum. 41 1998 2117 2121 (Pubitemid 29009369)
35. M. Mihara, M. Kotoh, N. Nishimoto, Y. Oda, E. Kumagai, N. Takagi, K. Tsunemi, Y. Ohsugi, T. Kishimoto, K. Yoshizaki, and Y. Takeda Humanized antibody to human interleukin-6 receptor inhibits the development of collagen arthritis in cynomolgus monkeys Clin. Immunol. 98 2001 319 326
36. N. Nishimoto, J. Hashimoto, N. Miyasaka, K. Yamamoto, S. Kawai, T. Takeuchi, N. Murata, D. Van Der Heijde, and T. Kishimoto Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an X-ray reader-blinded randomized controlled trial of tocilizumab Ann. Rheum. Dis. 66 2007 1162 1167 (Pubitemid 47309731)
37. M.C. Genovese, J.D. McKay, E.L. Nasonov, E.F. Mysler, N.A. da Silva, E. Alecock, T. Woodworth, and J.J. Gomez-Reino Interleukin-6 receptor inhibition with TCZ reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the TCZ in combination with traditional disease-modifying antirheumatic drug therapy study Arthritis Rheum. 58 2008 2968 2980
38. P. Emery, E. Keystone, H.P. Tony, A. Cantagrel, R. Van Vollenhoven, A. Sanchez, E. Alecock, J. Lee, and J. Kremer IL-6 receptor inhibition with TCZ improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-TNF biologics: results from a 24-week multicentre randomized placebo controlled trial Ann. Rheum. Dis. 67 2008 1516 1523
39. J.S. Smolen, A. Beaulieu, A. Rubbert-Roth, C. Ramos-Remus, J. Rovensky, E. Alecock, T. Woodworth, R. Alten, and OPTION Investigators Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): A double-blind, placebo-controlled, randomized trial Lancet 371 2008 987 997 (Pubitemid 351392039)
40. N. Nishimoto, N. Miyasaka, K. Yamamoto, S. Kawai, T. Takeuchi, J. Azuma, and T. Kishimoto Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy Mod. Rheumatol. 19 2009 12 19
41. Kremer, J.L.; Blanco, R.; Brzosko, M.; Burgos-Vargas, R.; Halland, A.M.; Vernon, E.; Ambs, P.; Fleischmann, R. (2010) Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate response to methotrexate at 1 year: the LITHE study. Arthritis Rheum. (Epub ahead of print).
42. G. Jones, A. Sebba, J. Gu, M.B. Lowenstein, A. Calvo, J.J. Gomez-Reino, D.A. Siri, M. Tomsic, E. Alecock, T. Woodworth, and M.C. Genovese Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study Ann. Rheum. Dis. 69 2010 88 96
43. T. Tanaka, A. Ogata, and M. Narazaki Tocilizumab for the treatment of rheumatoid arthritis Expert Rev. Clin. Immunol. 6 2010 843 854
44. J.L. Nam, K.L. Winthrop, R.F. Van Vollenhoven, K. Pavelka, G. Valesini, E.M. Hensor, G. Worthy, R. Landewe, J.S. Smolen, P. Emery, and M.H. Buch Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: A systematic literature review informing the EULAR recommendations for the management of RA Ann. Rheum. Dis. 69 2010 976 986
45. L. Obici, V. Perfetti, G. Palladini, R. Moratti, and G. Merlini Clinical aspects of systemic amyloid diseases Biochim. Biophys. Acta 1753 2005 11 22 (Pubitemid 41597427)
46. K. Hagihara, T. Nishikawa, T. Isobe, J. Song, Y. Sugamata, and K. Yoshizaki IL-6 plays a critical role in the synergistic induction of human serum amyloid A (SAA) gene when stimulated with proinflammatory cytokines as analyzed with an SAA isoform real-time quantitative RT-PCR assay system Biochem. Biophys. Res. Commun. 314 2004 363 369 (Pubitemid 38084725)
47. K. Hagihara, T. Nishikawa, Y. Sugamata, Y. Song, T. Isobe, T. Taga, and K. Yoshizaki Essential role of STAT3 in cytokine-driven NF-kB-mediated serum amyloid A gene expression Genes Cells 10 2005 1051 1063 (Pubitemid 41556074)
48. Y. Okuda, and K. Takasugi Successful use of a humanized anti-interleukin-6 receptor antibody, tocilizumab, to treat amyloid A amyloidosis complicating juvenile idiopathic arthritis Arthritis Rheum. 54 2006 2997 3000 (Pubitemid 44497781)
49. S. Nishida, K. Hagihara, Y. Shima, M. Kawai, Y. Kuwahara, J. Arimitsu, T. Hirano, M. Narazaki, A. Ogata, K. Yoshizaki, I. Kawase, T. Kishimoto, and T. Tanaka Rapid improvement of AA amyloidosis with humanised anti-interleukin 6 receptor antibody treatment Ann. Rheum. Dis. 68 2009 1235 1236
50. H. Sato, T. Sakai, T. Sugaya, Y. Otaki, K. Aoki, K. Ishii, H. Horizono, H. Otani, A. Abe, N. Yamada, H. Ishikawa, K. Nakazono, A. Murasawa, and F. Gejyo Tocilizumab dramatically ameliorated life-threatening diarrhea due to secondary amyloidosis associated with rheumatoid arthritis Clin. Rheumatol. 28 2009 1113 1116
51. D. Inoue, H. Arima, C. Kawanami, Y. Takiuchi, S. Nagano, S. Shimoji, M. Mori, S. Tabata, S. Yanagita, A. Matsushita, K. Nagai, Y. Imai, and T. Takahashi Excellent therapeutic effect of tocilizumab on intestinal amyloid a deposition secondary to active rheumatoid arthritis Clin. Rheumatol. 29 2010 1195 1197
52. N. Nishimoto, M. Sasai, Y. Shima, M. Nakagawa, T. Matsumoto, T. Shirai, T. Kishimoto, and K. Yoshizaki Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy Blood 95 2000 56 61 (Pubitemid 30017224)
53. N. Nishimoto, Y. Kanukura, K. Aozasa, T. Johkoh, M. Nakamura, S. Nakano, Y. Ikeda, T. Sasaki, K. Nishioka, M. Hara, H. Taguchi, Y. Kimura, Y. Kato, H. Asaoku, S. Kumagai, F. Kodama, H. Nakahara, K. Hagihara, K. Yoshizaki, and T. Kishimoto Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease Blood 106 2005 2627 2632 (Pubitemid 41510733)
54. S. Yokota, and T. Kishimoto Tocilizumab: molecular intervention therapy in children with systemic juvenile idiopathic arthritis Expert Rev. Clin. Immunol. 6 2010 735 743
55. F. De Benedetti, P. Pignatti, V. Gerioni, M. Massa, P. Sartirana, R. Caporali, C.M. Montecucco, A. Corti, F. Fantini, and A. Martini Differences in synovial fluid cytokine levels between juvenile and adult rheumatoid arthritis J. Rheumatol. 24 1997 1403 1409 (Pubitemid 27353389)
56. A.A. Romanovsky, M.C. Almeida, D.M. Aronoff, A.I. Ivanov, J.P. Konsman, A.A. Steiner, and V.F. Turek Fever and hypothermia in systemic inflammation: recent discoveries and revisions Front. Biosci. 10 2005 2193 2216 (Pubitemid 40905292)
57. S. Yokota, T. Miyamae, T. Imagawa, N. Iwata, S. Katakura, M. Mori, P. Woo, N. Nishimoto, K. Yoshizaki, and T. Kishimoto Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis Arthritis Rheum. 52 2005 818 825 (Pubitemid 40365104)
58. S. Yokota, T. Imagawa, M. Mori, T. Miyamae, Y. Aihara, S. Takei, N. Iwata, H. Umebayashi, T. Murata, M. Miyoshi, M. Tomita, N. Nishimoto, and T. Kishimoto Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: A randomized, double-blind, placebo-controlled, withdrawal phase III trial Lancet 371 2008 998 1006 (Pubitemid 351389534)
59. F. De Benedetti, H. Brunner, N. Ruperto, S. Wright, A. Kenwright, R. Cuttica, P. Woo, R. Schneider, D. Lovell, and A. Martini From biology to classification and targeted therapy in juvenile idiopathic arthritis Ann. Rheum. Dis. 69 Suppl. 3 2010 146
60. B. Fautrel Adult-onset Still disease Best Pract. Res. Clin. Rheumatol. 22 2008 773 792
61. M. Iwamoto, H. Nara, D. Hirata, S. Minota, N. Nishimoto, and K. Yoshizaki Humanized monoclonal anti-interleukin-6 receptor antibody for treatment of intractable adult-onset Still's disease Arthritis Rheum. 46 2002 3388 3389 (Pubitemid 35453552)
62. H. Nakahara, T. Mima, N. Yoshino-Hoshino, M. Matsushita, J. Hashimoto, and N. Nishimoto A case report of a patient with refractory adult-onset Still's disease who was successfully treated with tocilizumab over 6 years Mod. Rheumatol. 19 2009 69 72
63. M. De Bandt, and B. Saint-Marcoux Tocilizumab for multirefractory adult-onset Still's disease Ann. Rheum. Dis. 68 2009 153 154
64. K. Matsumoto, T. Nagashima, S. Takatori, Y. Kawahara, M. Yagi, M. Iwamoto, H. Okazaki, and S. Minota Glucocorticoid and cyclosporine refractory adult onset Still's disease successfully treated with tocilizumab Clin. Rheumatol. 28 2009 485 487
65. M.L. Cunha, J. Wagner, A. Osawa, and M. Scheinberg The effect of tocilizumab on the uptake of 18FDG-PET imaging in patients with adult-onset Still's disease Rheumatology 49 2010 1014 1016
66. K. Sumida, Y. Ubara, J. Hoshino, T. Suwabe, R. Hiramatsu, E. Hasegawa, N. Hayami, M. Yamanouchi, N. Sawa, F. Takemoto, and K. Takaichi Etanercept-refractory adult-onset Still's disease with thrombotic thrombocytopenic purpura successfully treated with tocilizumab Clin. Rheumatol. 29 2010 1191 1194
67. M. Yoshimura, J. Makiyama, T. Koga, T. Miyashita, Y. Izumi, T. Torigoshi, S. Motokawa, K. Eguchi, and K. Migita Successful treatment with tocilizumab in a patient with refractory adult-onset Still's disease (AOSD) Clin. Exp. Rheumatol. 28 2010 141 142
68. K. Perdan-Pirkmajer, S. Praprotnik, and M. Tomsic A case of refractory adult-onset Still's disease successfully controlled with tocilizumab and a review of the literature Clin. Rheumatol. 29 2010 1465 1467
69. H. Itoh Novel therapy for Crohn's disease targeting IL-6 signaling Expert Opin. Ther. Targets 8 2004 287 294
70. K. Mitsuyama, A. Toyonaga, and E. Sasaki Soluble interleukin-6 receptors in inflammatory bowel disease: relation to circulating interleukin-6 Gut 36 1995 45 49
71. T. Hosokawa, K. Kusugami, K. Ina, T. Ando, M. Shinoda, A. Imada, M. Ohsuga, T. Sakai, T. Matsuura, K. Ito, and K. Kaneshiro Interleukin-6 and soluble interleukin-6 receptor in the colonic mucosa of inflammatory bowel disease J. Gastroenterol. Hepatol. 14 1999 987 996 (Pubitemid 29487295)
72. M. Yamamoto, K. Yoshizaki, T. Kishimoto, and H. Ito IL-6 is required for the development of Th1-cell mediated murine colitis J. Immunol. 164 2000 4878 4882 (Pubitemid 30238092)
73. H. Ito, M. Takazoe, Y. Fukuda, T. Hibi, K. Kusugami, A. Andoh, T. Matsumoto, T. Yamamura, J. Azuma, N. Nishimoto, K. Yoshizaki, T. Shimoyama, and T. Kishimoto A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease Gastroenterology 126 2004 989 996 (Pubitemid 38451170)
74. S. Grivennikov, E. Karin, J. Terzic, D. Mucida, G.-Y. Yu, S. Vallabhapurapu, J. Scheller, S. Rose-John, H. Cheroutre, L. Eckmann, and M. Karin IL-6 and STAT3 are required for survival of intestinal epithelial cells and development of colitis associated cancer Cancer Cell 15 2009 103 113
75. C. Salvarani, F. Cantini, and G.G. HunDer Polymyalgia rheumatica and giant-cell arteritis Lancet 372 2008 234 245 (Pubitemid 351997438)
76. S.E. Gabriel, J. Sunku, C. Salvarani, W.M. O'Fallon, and G.G. HunDer Adverse outcomes of anti-inflammatory therapy among patients with polymyalgia rheumatica Arthritis Rheum. 40 1997 1873 1878 (Pubitemid 27452540)
77. M.A. Cimmino, C. Salvarani, P. Macchioni, R. Gerli, B.E. Bartoloni, C. Montecucco, and R. Caporali Long-term follow-up of polymyalgia rheumatica patients treated with methotrexate and steroids Clin. Exp. Rheumatol. 26 2008 395 400 (Pubitemid 352003206)
78. C. Salvarani, F. Cantini, L. Niccoli, P. Macchioni, D. Consonni, G. Bajocchi, M. Vinceti, M.G. Catanoso, L. Pulsarelli, R. Meliconi, and L. Boiardi Acute-phase reactants and the risk of relapse/recurrence in polymyalgia rheumatica: A prospective followup study Arthritis Rheum. 53 2005 33 38 (Pubitemid 40216349)
79. L. Alvarez-Rodriguez, M. Lopez-Hoyos, M.J. Marin, J. Calvo-Alen, R. Blanco, E. Aurrecoechea, M. Ruiz-Soto, and V.M. Martinez-Teboada Circulating cytokines in active polymyalgia rheumatica Ann. Rheum. Dis. 69 2010 263 269
80. K. Hagihara, I. Kawase, T. Tanaka, and T. Kishimoto Tocilizumab ameliorates clinical symptoms in polymyalgia rheumatica J. Rheumatol. 37 2010 1075 1076
81. D.J. McCarty, J.D. O'Duffy, J.D. Pearson, and J.B. Hunter Remitting, seronegative symmetrical synovitis with pitting edema JAMA 254 1985 2763 2767 (Pubitemid 16243296)
82. T. Oide, S. Ohara, K. Oguchi, M. Maruyama, M. Yazawa, K. Inoue, Y. Sekijima, T. Tokuda, and S. Ikeda Remitting seronegative symmetrical synovitis with pitting edema (RS3PE) syndrome in Nagano, Japan: clinical, radiological, and cytokine studies of 13 patients Clin. Exp. Rheumatol. 22 2004 91 98 (Pubitemid 38232814)
83. K. Arima, T. Origuchi, M. Tamai, N. Iwanaga, Y. Izumi, M. Huang, F. Tanaka, M. Kamachi, K. Aratake, H. Nakamura, H. Ida, M. Uetani, A. Kawakami, and K. Eguchi RS3PE syndrome presenting as vascular endothelial growth factor associated disorDer Ann. Rheum. Dis. 64 2005 1653 1655 (Pubitemid 41532054)
84. S. Kawashiro, M. Nakano, A. Kawakami, and K. Eguchi Monitoring of therapeutic efficacy in a patient with RS3PE syndromes by serologic and radiographic methods Rheumatol. Int. 30 2010 1677 1680
85. T. Tanaka, K. Hagihara, Y. Shima, M. Narazaki, A. Ogata, I. Kawase, and T. Kishimoto Treatment of a patient with remitting seronegative, symmetrical synovitis with pitting oedema with a humanized anti-interleukin-6 receptor antibody, tocilizumab Rheumatology 49 2010 826 828
86. V.M. Marinez-Taboada, L. Alvarez, M. RuizSoto, M.J. Marin-Vidalled, and M. Lopez-Hoyos Giant cell arteritis and polymyalgia rheumatica: role of cytokines in the pathogenesis and implications for treatment Cytokine 44 2008 207 220
87. P. Ghosh, F.A. Borg, and B. Dasgupta Current understanding and management of giant cell arteritis and polymyalgia rheumatica Expert Rev. Clin. Immunol. 6 2010 913 928
88. M.C. Park, S.W. Lee, Y.B. Park, and S.K. Lee Serum cytokine profiles and their correlations with disease activity in Takayasu's arteritis Rheumatology 45 2006 545 548
89. M. Moris, E. Daina, S. Gamba, S. Bonazzola, and G. Remuzzi Interleukin-6 and RANTES in Takayasu arteritis: A guide for therapeutic decisions? Circulation 100 1999 1788 1790
90. N. Nishimoto, H. Nakahara, N. Yoshio-Hoshino, and T. Mima Successful treatment of a patient with Takayasu arteritis using a humanized anti-interleukin-6 receptor antibody Arthritis Rheum. 58 2008 1197 1200 (Pubitemid 351564023)
91. Seitz, M.; Reichenbach, S.; Bonel, H.M.; Adler, S.; Wermelinger, F.; Villiger, P.M. (2011) Rapid induction of remission in large vessel vasculitis by IL-6 blockade. Swiss Med. Wkly (Epub ahead of print).
92. M.C. Cid, J. Haernandez-Rodriguez, M.J. Esteban, M. Cebrian, Y.S. Gho, C. Font, A. Urbano-Marquez, J.M. Grau, and H.K. Kleinman Tissue and serum angiogenic activity is associated with low prevalence of ischemic complications in patients with giant-cell arteritis Circulation 106 2002 1664 1671
93. J. Hernandez-Rodriguez, M. Segarra, C. Vilardell, M. Sanchez, A. Garcia-Martinez, M.J. Esteban, J.M. Grau, A. Urbano-Marquez, D. Colomer, H.K. Kleinman, and M.C. Cid Elevated production of interleukin-6 is associated with a lower incidence of disease-related ischemic events in patients with giant-cell arteritis: angiogenic activity of interleukin-6 as a potential protective mechanism Circulation 107 2003 2428 2434 (Pubitemid 36605224)
94. J.D. Reveille, and F.C. Arnett Spondyloarthritis: update on pathogenesis and management Am. J. Med. 118 2005 592 603 (Pubitemid 40732696)
95. J. Braun, and J. Sieper Ankylosing spondylitis Lancet 369 2007 1379 1390 (Pubitemid 46590387)
96. I.B. Wu, and R.A. Schwartz Reiter's syndrome: the classic triad and more J. Am. Acad. Dermatol. 59 2008 113 121
97. K.P. Metsarinne, D.C. Nordstrom, Y.T. Konttinen, A.M. Teppo, and F.Y. Fyhrquist Plasma interleukin-6 and renin substrate in reactive arthritis, rheumatoid arthritis, and systemic lupus erythematosus Rheumatol. Int. 12 1992 93 96
98. R.H. Straub, L. Paimela, R. Peltomaa, J. Scholmerich, and M. Leirisalo-Repo Inadequately low levels of steroid hormones in relation to interleukin-6 and tumor necrosis factor in untreated patients with early rheumatoid arthritis and reactive arthritis Arthritis Rheum. 46 2002 654 662 (Pubitemid 34214248)
99. R. Singh, A. Aggarwal, and R. Misra Th1/Th17 cytokine profiles in patients with reactive arthritis/undifferentiated spondyloarthropathy J. Rheumatol. 34 2007 2285 2290 (Pubitemid 350076892)
100. T. Tanaka, Y. Kuwahara, Y. Shima, T. Hirano, M. Kawai, M. Ogawa, J. Arimitsu, K. Hagihara, M. Narazaki, A. Ogata, I. Kawase, and T. Kishimoto Successful treatment of reactive arthritis with a humanized anti-interleukin-6 receptor antibody, tocilizumab Arthritis Rheum. 61 2009 1762 1764
101. D. Wendling, E. Racadot, E. Toussirot, and J. Wijdens Combination therapy of anti-CD4 and anti-IL6 monoclonal antibodies in a case of severe spondyloarthropathy Br. J. Rheumatol. 35 1996 1330 (Pubitemid 27032963)
102. J.C. Henes, M. Horger, I. Guenaydin, L. Kanz, and I. Koetter Mixed response to tocilizumab for ankylosing spondylitis Ann. Rheum. Dis. 69 2010 2217 2218
103. D. Wendling, M. Bossert, and C. Prati Short-term effect of IL-6 inhibition in spondyloarthritis Joint Bone Spine 77 2010 624 625
104. L. Brulhart, M.J. Nissen, P. Chevallier, and C. Gabay Tocilizumab in a patient with ankylosing spondylitis and Crohn's disease refractory to TNF antagonists Joint Bone Spine 77 2010 625 626
105. Shima, Y.; Tomita, T.; Ishii, T.; Morishima, A.; Maeda, Y.; Ogata, A.; Kishimoto, T.; Tanaka, T. (2011) Tocilizumab, a humanized anti-interleukin-6 receptor antibody, ameliorated clinical symptoms and MRI findings of a patient with ankylosing spondylitis. Mod. Rheumatol. (Epub ahead of print).
106. R.P. Rapini, and N.B. Warner Relapsing polychondritis Clin. Dermatol. 24 2006 482 485 (Pubitemid 44750558)
107. T. Stabler, J.C. Piette, X. Chevalier, A. Marini-Portugal, and V.B. Kraus Serum cytokine profiles in relapsing polychondritis suggest monocyte/macrophage activation Arthritis Rheum. 50 2004 3663 3667 (Pubitemid 39488695)
108. M. Kawai, K. Hagihara, T. Hirano, Y. Shima, Y. Kuwahara, J. Arimitsu, M. Narazaki, A. Ogata, I. Kawase, T. Kishimoto, and T. Tanaka Sustained response to tocilizumab, anti-interleukin-6 receptor antibody, in two patients with refractory relapsing polychondritis Rheumatology 48 2009 319 320
109. A. Gabrielli, E.V. Avvedimento, and T. Krieg Scleroderma N. Engl. J. Med. 360 2009 1989 2003
110. M. Hasegawa, S. Sato, M. Fujimoto, H. Ihn, K. Kikuchi, and K. Takehara Serum levels of interleukin 6 (IL-6), oncostatin M, soluble IL-6 receptor, and soluble gp130 in patients with systemic sclerosis J. Rheumatol. 25 1998 308 313 (Pubitemid 28088260)
111. S. Sato, M. Hasegawa, and K. Takehara Serum levels of interleukin-6 and interleukin-10 correlate with total skin thickness score in patients with systemic sclerosis J. Dermatol. Sci. 27 2001 140 146 (Pubitemid 32781022)
112. R.M. Gallucci, E.G. Lee, and J.J. Tomasek IL-6 modulates alpha-smooth muscle actin expression in dermal fibroblasts from IL-6-deficient mice J. Invest. Dermatol. 126 2006 561 568 (Pubitemid 43255642)
113. T.Z. Kirk, M.E. Mark, C.C. Chua, B.H. Chua, and M.D. Mayes Myofibroblasts from scleroderma skin synthesize elevated levels of collagen and tissue inhibitor of metalloproteinase (TIMP-1) with two forms of TIMP-1 J. Biol. Chem. 270 1995 3423 3428
114. Y. Kuwahara, Y. Shima, D. Shirayama, M. Kawai, K. Hagihara, T. Hirano, J. Arimitsu, A. Ogata, T. Tanaka, and I. Kawase Quantification of hardness, elasticity and viscosity of the skin of patients with systemic sclerosis using a novel sensing device (Vesmeter): A proposal for a new outcome measurement procedure Rheumatology 47 2008 1018 1024 (Pubitemid 351865926)
115. Y. Shima, Y. Kuwahara, H. Murota, S. Kitaba, M. Kawai, T. Hirano, J. Arimitsu, M. Narazaki, K. Hagihara, A. Ogata, I. Katayama, I. Kawase, T. Kishimoto, and T. Tanaka The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab Rheumatology 49 2010 2408 2412
116. O. Kowal-Bielecka, R. Landewe, J. Avouac, S. Chwiesko, I. Miniati, L. Czirjak, P. Clements, C. Denton, D. Farge, K. Fligelstone, I. Foldvari, D.E. Furst, U. Muller-Ladner, J. Seibold, R.M. Silver, K. Takehara, B.G. Toth, A. Tyndall, G. Valentini, F. Van den Hoogen, F. Wigley, F. Zulian, M. Matucci-Cerinic, and EUSTAR Co-Authors EULAR recommendations for the treatment of systemic sclerosis: A report from the EULAR scleroderma trials and research group (EUSTAR) Ann. Rheum. Dis. 68 2009 620 628
117. M.C. Dalakas Immunotherapy of myositis: issues, concerns and future prospects Nat. Rev. Rheumatol. 6 2010 129 137
118. I. Lundberg, J.A. Ulfgren, P. Nyberg, U. Andersson, and L. Klareskog Cytokine production in muscle tissue of patients with idiopathic inflammatory myopathies Arthritis Rheum. 40 1997 865 874 (Pubitemid 27200003)
119. H. Lepidi, V. Frances, D. Figarella-Branger, C. Bartoli, A. Machado-Baeta, and J.F. Pellissier Local expression of cytokines in idiopathic inflammatory myopathies Neuropathol. Appl. Neurobiol. 24 1998 73 79 (Pubitemid 28105417)
120. F. Scuderi, F. Mannela, M. Marino, C. Provenzano, and E. Bartoccioni IL-6-deficient mice show impaired inflammatory response in a model of myosin-induced experimental myositis J. Neuroimmunol. 176 2006 9 15 (Pubitemid 44080332)
121. N. Okiyama, T. Sugihara, Y. Iwakura, H. Yokozeki, N. Miyasaka, and H. Kohsaka Therapeutic effects of interleukin-6 blockade in a murine model of polymyositis that does not require interleukin-17A Arthritis Rheum. 60 2009 2505 2512
122. G. Ruitz-Irastorza, M.A. Khamashta, G. Castellino, and G.R. Hughes Systemic lupus erythematosus Lancet 357 2001 1027 1032 (Pubitemid 32285401)
123. M. Linker-Isaraeli, R.J. Deans, D.J. Wallace, J. Prehn, T. Ozeri-Chen, and J.R. Klinenberg Elevated levels of endogenous IL-6 in systemic lupus erythematosus: A putative role in pathogenesis J. Immunol. 147 1991 117 123
124. G. Grondal, I. Gunnarsson, J. Ronnelid, S. Rogberg, L. Klareskog, and I. Lundberg Cytokine production, serum levels and disease activity in systemic lupus erythematosus Clin. Exp. Rheumatol. 18 2000 565 570
125. E. Peterson, A.D. Robertson, and W. Emlen Serum and urinary interleukin-6 in systemic lupus erythematosus Lupus 5 1996 571 575 (Pubitemid 27035726)
126. M. Iwano, K. Dohi, E. Hirata, N. Kurumatani, Y. Horii, H. Shiiki, A. Fukatsu, T. Matsuda, T. Hirano, T. Kishimoto, and K. Dohi Urinary levels of IL-6 in patients with active lupus nephritis Clin. Nephrol. 40 1993 16 21 (Pubitemid 23221728)
127. S. Hirohata, and T. Miyamoto Elevated levels of interleukin-6 in cerebrospinal fluid from patients with systemic lupus erythematosus and central nervous system involvement Arthritis Rheum. 33 1990 644 649 (Pubitemid 20166565)
128. M. Mihara, N. Takagi, Y. Takeda, and Y. Ohsugi IL-6 receptor blockage inhibits the onset of autoimmune kidney disease in NZB/W F1 mice Clin. Exp. Immunol. 112 1998 397 402 (Pubitemid 28267419)
129. B. Liang, D.B. Gardner, D.E. Griswold, P.J. Bugelski, and X.Y. Song Anti-interleukin-6 monoclonal antibody inhibits autoimmune responses in a murine model of systemic lupus erythematosus Immunology 119 2006 296 305 (Pubitemid 44571047)
130. G.G. Illei, Y. Shirota, C.H. Yarboro, J. Daruwalla, E. Tackey, K. Takada, T. Fleisher, J.E. Balow, and P.E. Lipsky Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study Arthritis Rheum. 62 2010 542 552
131. D. Mendes, M. Correcia, M. Barbedo, T. Vaio, and M. Mota Behcet's disease - a contemporary review J. Autoimmun. 32 2009 178 188
132. A. Kulaber, I. Tugal-Tutkun, P. Sibel, G. Akman-Demir, F. Kaneko, A. Gul, and G. Saruhan-Direskeli Pro-inflammatory cellular immune response in Behcet's disease Rheumatol. Int. 27 2007 1113 1118 (Pubitemid 47373949)
133. S. Hirohata, H. Oka, and Y. Mizushima Streptococcal-related antigens stimulate production of IL6 and interferon-gamma by T cells from patients with Behcet's disease Cell. Immunol. 140 1992 410 419
134. J.L. Mege, N. Dilsen, V. Sanguedolce, A. Gul, P. Bongrand, H. Roux, L. Ocal, M. Inanc, and C. Capo Overproduction of monocyte derived tumor necrosis factor alpha, interleukin (IL) 6, IL-8 and increased neutrophil superoxide generation in Behcet's disease. A comparative study with familial Mediterranean fever and healthy subjects J. Rheumatol. 20 1993 1544 1549 (Pubitemid 24027329)
135. S. Hirohata, K. Isshiki, H. Oguchi, T. Ohse, H. Haraoka, A. Takeuchi, and T. Hashimoto Cerebrospinal fluid interleukin-6 in progressive neuro-Behcet's syndrome Clin. Immunol. Immunopathol. 82 1997 12 17 (Pubitemid 27049067)
136. R.C. Rachel A look at autoimmunity and inflammation in the eye J. Clin. Invest. 120 2010 3073 3083
137. S. Hohki, N. Ohguro, H. Haruta, K. Nakai, F. Terabe, S. Serada, M. Fujimoto, S. Nomura, H. Kawahata, T. Kishimoto, and T. Naka Blockade of interleukin-6 signaling suppresses experimental autoimmune uveoretinitis by the inhibition of inflammatory Th17 responses Exp. Eye Res. 91 2010 162 170
138. C.K. Glass, K. Saijo, B. Winner, M.C. Marchetto, and F.H. Gage Mechanisms underlying inflammation in neurodegeneration Cell 140 2010 918 934
139. L. Steinman Nuanced roles of cytokines in three major human brain disorders J. Clin. Invest. 118 2008 3557 3563
140. D. Maimone, S. Gregory, B.G. Arnason, and A.T. ReDer Cytokine levels in the cerebrospinal fluid and serum of patients with multiple sclerosis J. Neuroimmunol. 32 1991 67 74
141. V. Navikas, D. Matusevicius, M. Soderstrom, S. Fredrikson, P. Kivisakk, A. Ljungdahl, B. Hojeberg, and H. Link Increased interleukin-6 mRNA expression in blood and cerebrospinal fluid mononuclear cells in multiple sclerosis J. Neuroimmunol. 64 1996 63 69 (Pubitemid 26052075)
142. C. Lock, G. Hermans, R. Pedotti, A. Brendolan, E. Schadt, H. Garren, A. Langer-Gould, S. Strober, B. Cannella, J. Allard, P. Klonowski, A. Austin, N. Lad, N. Kaminski, S.J. Galli, J.R. Oksenberg, C.S. Raine, R. Heller, and L. Steinman Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis Nat. Med. 8 2002 500 508 (Pubitemid 34546753)
143. K. Gijbels, J. Van Damme, P. Proost, W. Put, H. Carton, and A. Billiau Interleukin 6 production in the central nervous system during experimental autoimmune encephalomyelitis Eur. J. Immunol. 20 1990 233 235 (Pubitemid 20087053)
144. S. Serada, M. Fujimoto, M. Mihara, N. Koike, Y. Ohsugi, S. Nomura, H. Yoshida, T. Nishikawa, F. Terabe, T. Ohkawara, T. Takahashi, B. Ripley, A. Kimura, T. Kishimoto, and T. Naka IL-6 blockade inhibits the induction of myelin antigen-specific Th17 cells and Th1 cells in experimental autoimmune encephalomyelitis Proc. Natl. Acad. Sci. USA 105 2008 9041 9046
145. S. Jarius, and B. Wildemann AQP4 antibodies in neuromyelitis optica: diagnostic and pathogenetic relevance Nat. Rev. Neurol. 6 2010 383 392
146. Uzawa, A.; Mori, M.; Ito, M.; Uchida, T.; Hayakawa, S.; Masuda, S.; Kuwabara, S. (2009) Markedly increased CSF interleukin-6 levels in neuromyelitis optica, but not in multiple sclerosis. J. Neurol. (Epub ahead of print).
147. S. Icoz, E. Tuzun, M. Kurtuncu, H. Durmus, M. Mutlu, M. Eraksoy, and G. Akman-Demir Enhanced IL-6 production in aquaporin-4 antibody positive neuromyelitis optica patients Int. J. Neurosci. 120 2010 71 75
148. P.W. Collins, and C.L. Percy Advances in the understanding of acquired hemophilia A: implications for clinical practice Br. J. Haematol. 148 2009 182 194
149. Nishida, S.; Kawasaki, T.; Kashiwagi, H.; Morishima, A.; Hishitani, Y.; Kawai, M.; Hirano, T.; Ishii, T.; Hagihara, K.; Shima, Y.; Narazaki, M.; Ogata, A.; Oka, Y.; Kishimoto, T.; Tanaka, T. (2011) Successful treatment of acquired hemophilia A, complicated by chronic GVHD, with tocilizumab. Mod. Rheumatol. (Epub ahead of print).
150. U. Gergis, J. Arnason, R. Yantiss, T. Shore, U. Wissa, E. Feldman, and T. Woodworth Effectiveness and safety of tocilizumab, an anti-interleukin-6 receptor monoclonal antibody, in a patient with refractory GI graft-versus-host disease J. Clin. Onocol. 28 2010 602 604
151. M.F. McDermott, I. Aksentijevick, J. Galon, E.M. McDermott, B.W. Ogunkolande, M. Centola, E. Mansfield, M. Gadina, L. Karenko, T. Pettersson, J. McCarthy, D.M. Frucht, M. Aringer, Y. Torosyan, A.M. Teppo, M. Wilson, H.M. Karaarslan, Y. Wan, I. Todd, G. Wood, R. Schlimgen, T.R. Kumarajeewa, S.M. Cooper, J.P. Vella, C.I. Amos, J. Mulley, K.A. Quane, M.G. Molloy, A. Ranki, R.J. Powell, G.A. Hitman, J.J. O'Shea, and D.L. Kastner Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes Cell 97 1999 133 144 (Pubitemid 29165896)
152. Vaitla, P.M.; Radford, P.M.; Tighe, P.J.; Powell, R.J.; McDermott, E.M.; Todd, I.; Drewe, E. (2011) Role of interleukin-6 (IL-6) in a patient with TRAPS revealed by treatment with tocilizumab (anti-IL-6 receptor monoclonal antibody). Arthritis Rheum. (Epub ahead of print).
153. Campbell, L.; Chen, C.; Bhagat, S.S.; Parker, R.A.; Ostor, A.J. (2010) Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: A systemic literature review and meta-analysis of randomized controlled trials. Rheumatology (Epub ahead of print).
154. V. Wallenius, K. Wallenius, B. Ahren, M. Rudling, H. Carlsten, S.L. Dickson, C. Ohlsson, and J.-O. Jansson Interleukin-6-deficient mice develop mature-onset obesity Nat. Med. 8 2002 75 79 (Pubitemid 34101732)
155. T. Kishimoto IL-6: from its discovery to clinical applications Int. Immunol. 22 2010 347 352
156. M. Fujimoto, S. Serada, M. Mihara, Y. Uchiyama, H. Yoshida, N. Koike, Y. Ohsugi, T. Nishikawa, B. Ripley, A. Kimura, T. Kishimoto, and T. Naka Interleukin-6 blockade suppresses autoimmune arthritis in mice by the inhibition of inflammatory Th17 responses Arthritis Rheum. 58 2008 3710 3719